Wesley Jackson, PhD, spent years conducting post-doctoral research and writing grants, all the while setting the wheels in motion to launch Valitor.
Valitor is developing VLTR-557 a long-lasting anti-VEGF. The technology platform, a multivalent polymer (MVP), is integral to VLTR-557.
With Firas Rahhal, MD, Dr. Jackson shares why he stuck with the science behind Valitor during his PhD studies and beyond. He also discusses why he kept his sights set on entrepreneurship while his colleagues pursued academic careers.
Long story short: Dr. Jackson worked for a medtech start-up as a college student and fell for the “we’re all in this together” culture of the company.
As the scientist behind MVP, Dr. Jackson says his commitment and passion for the company and its products give Valitor a competitive edge. A larger company may shelve an acquired product, leaving it to sit ignored. The start-up has ownership, and will maintain that responsibility for as long as it takes.
Listen to the podcast today to discover:
[Listen Now]
Resources
Wesley Jackson, PhD: linkedin.com/in/wesleymjackson
Firas Rahhal, MD: ois.net/firas-m-rahhal-md
Valitor: valitorbio.com